Azithromycin
- Generic Name
- Azithromycin
- Brand Names
- Azasite, Zithromax, Zmax
- Drug Type
- Small Molecule
- Chemical Formula
- C38H72N2O12
- CAS Number
- 83905-01-5
- Unique Ingredient Identifier
- J2KLZ20U1M
- Background
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...
- Indication
Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis
- Associated Therapies
- -
Azithromycin in Hospitalized COVID-19 Patients
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT04359316
- Locations
- 🇮🇷
Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 16
- Registration Number
- NCT04359953
- Locations
- 🇫🇷
CHU de Strasbourg, Strasbourg, France
Treatment for COVID-19 in High-Risk Adult Outpatients
- Conditions
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 289
- Registration Number
- NCT04354428
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Tulane University, New Orleans, Louisiana, United States
🇺🇸University of Washington Coordinating Center, Seattle, Washington, United States
A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04353661
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Duke Asthma Allergy and Airway Center, Durham, North Carolina, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Abderrahmane Mami Hospital
- Registration Number
- NCT04351919
- Locations
- 🇹🇳
Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 456
- Registration Number
- NCT04349592
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2023-12-06
- Target Recruit Count
- 1500
- Registration Number
- NCT04349826
- Locations
- 🇳🇵
Patan Hospital, Lalitpur, Bagmati, Nepal
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- LCMC Health
- Target Recruit Count
- 22
- Registration Number
- NCT04344444
- Locations
- 🇺🇸
University Medical Center New Orleans, New Orleans, Louisiana, United States
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus
- Conditions
- Interventions
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 122
- Registration Number
- NCT04344379
- Locations
- 🇫🇷
Hopial Avicenne, Bobigny, France
🇫🇷Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France
🇫🇷Hôpital Saint Antoine, Paris, France
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT04341727
- Locations
- 🇺🇸
Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.